| scholarly article | Q13442814 |
| P2093 | author name string | Donald J Brambilla | |
| David R Gretch | |||
| Chihiro Morishima | |||
| Minjun Chung | |||
| Ka Wing Ng | |||
| P2860 | cites work | Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0, International Unit assay and the National Genetics Institute HCV Superquant assay | Q27471191 |
| Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay | Q27471213 | ||
| Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum | Q27472747 | ||
| Comparative Evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR Version 2.0 Assays for Quantification of Hepatitis C Virus RNA in Serum | Q27473432 | ||
| Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon | Q27478427 | ||
| Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology | Q27485690 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group | Q27861083 | ||
| Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group | Q29620719 | ||
| Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays. | Q33961960 | ||
| Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma | Q33968714 | ||
| Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics | Q33970328 | ||
| Interferon treatment for chronic hepatitis C infection in hemophiliacs--influence of virus load, genotype, and liver pathology on response. | Q42977054 | ||
| Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. | Q42980950 | ||
| Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison | Q42985824 | ||
| Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group | Q42990634 | ||
| Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group | Q42993649 | ||
| Loss of serum HCV RNA at week 4 of interferon‐α therapy is associated with more favorable long‐term response in patients with chronic hepatitis C | Q43038103 | ||
| Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus | Q43039266 | ||
| Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-alpha therapy | Q43040510 | ||
| Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice | Q43048089 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 421-425 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Journal of Clinical Microbiology | Q4041880 |
| P1476 | title | Strengths and limitations of commercial tests for hepatitis C virus RNA quantification | |
| P478 | volume | 42 |
| Q27487878 | A Novel Diagnostic Target in the Hepatitis C Virus Genome |
| Q53692197 | Biological and nanotechnological applications using interactions between ionic liquids and nucleic acids. |
| Q35027939 | Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C |
| Q27473038 | Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5 |
| Q27481004 | Comparison of Performance Characteristics of Three Real-Time Reverse Transcription-PCR Test Systems for Detection and Quantification of Hepatitis C Virus |
| Q37511219 | Evaluation of the core antigen assay as a second-line supplemental test for diagnosis of active hepatitis C virus infection |
| Q43001559 | HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial |
| Q27490792 | Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C |
| Q43037979 | Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method |
| Q37156650 | Performance characteristics of a quantitative TaqMan hepatitis C virus RNA analyte-specific reagent |
| Q27488563 | Performance of the Abbott Real-Time PCR Assay Using m2000sp and m2000rt for Hepatitis C Virus RNA Quantification |
| Q33694159 | Processes to manage analyses and publications in a phase III multicenter randomized clinical trial |
| Q37509316 | Rational design of DNA sequences for nanotechnology, microarrays and molecular computers using Eulerian graphs |
| Q37397022 | Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. |
| Q27001036 | Structure, stability and behaviour of nucleic acids in ionic liquids |
| Q39989744 | Use of the MagNA pure LC automated nucleic acid extraction system followed by real-time reverse transcription-PCR for ultrasensitive quantitation of hepatitis C virus RNA |
| Q36188710 | Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials |
Search more.